Stretch Marks Treatment Market By Treatment Type (Topical Products [Tretinoin, Hyaluronic Acid, Centella Asiatica, Glycolic Acid, Emollients & Oils], Procedural Treatments [Microneedling, Radiofrequency Microneedling, Laser & Light Therapy, Chemical Peels, Microdermabrasion, Other Combination Treatments]), By Stretch Mark Type (Striae Rubrae, Striae Albae, Striae Gravidarum, Other Striae), By End User (Dermatology Clinics, Aesthetic Clinics & Medical Spas, Hospitals & Plastic Surgery Centers, Home-Use Consumers), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Stretch Marks Treatment Market: From Topical Care to Advanced Skin Remodeling and the Expanding Science of Striae Management

The Global Stretch Marks Treatment Market was valued at USD 2.96 billion in 2025 and is projected to reach USD 4.54 billion by 2032, expanding at a CAGR of 6.3% during 2026–2032.

 

Tretinoin is nevertheless one of the most clinically established pharmaceutical options used off-label for early striae rubrae. FDA-regulated tretinoin products are approved for indications such as acne vulgaris and, for specific formulations, mitigation of fine facial wrinkles associated with photoaging—not for stretch marks. Tretinoin is an active vitamin A metabolite that activates retinoic acid nuclear receptors RARα, RARβ, and RARγ, influencing gene expression, protein synthesis, and epithelial growth and differentiation. Dermatology evidence indicates that topical tretinoin can make early stretch marks less noticeable, although irritation limits use and pregnancy materially restricts the addressable population for retinoid-based treatment.

 

However, epidemiological estimates indicate a very large potential patient base, with striae occurring in 43%–88% of pregnancies, 6%–86% of adolescents, and around 43% of individuals with obesity; applying these prevalence ranges to birth data suggests that in the U.S., with 3.61 million births in 2025, approximately 1.5–3.2 million women annually may develop pregnancy-related stretch marks, while globally, with about 132 million births in 2024, an estimated 56.8–116.2 million women per year are affected by pregnancy-related striae alone.

 

Why do topical products remain the highest-volume treatment category?

Based on the supplied market segmentation, topical products account for approximately 55%–60% of stretch-mark treatments, reflecting their accessibility, low upfront cost, ability to be used at home, and particularly strong adoption during pregnancy and the early appearance of striae. The segment includes prescription tretinoin, hyaluronic-acid formulations, centella-containing products, glycolic-acid preparations, emollients, oils, and other cosmetic creams and serums.

Tretinoin has the strongest pharmaceutical positioning within this group because its benefit is concentrated in early striae rather than mature white scars. The American Academy of Dermatology reports that people who applied prescription tretinoin to early stretch marks experienced greater improvement than untreated patients in clinical studies. This creates a narrow but clinically differentiated prescription opportunity among non-pregnant consumers who seek treatment before lesions mature.

Hyaluronic acid occupies a different commercial position. The AAD reports that two large studies found that applying hyaluronic acid to early stretch marks made them less noticeable. Its widespread presence in cosmetic skincare, non-prescription availability, and suitability for formulation with moisturizers make it easier to incorporate into pregnancy and body-care product portfolios than prescription retinoids.

Centella asiatica, glycolic acid, cocoa butter, shea butter, almond oil, rosehip oil, olive oil, and similar ingredients broaden the consumer market, but evidence is uneven. Basic emollients mainly improve hydration, softness, and itching rather than rebuilding established dermal scars. AAD reviews found that commonly promoted products such as cocoa butter, almond oil, olive oil, and vitamin E did not reliably prevent stretch marks in controlled studies, while systematic evidence has also failed to establish high-quality proof that most topical preparations prevent pregnancy-related striae. This gap between high consumer usage and limited clinical efficacy leaves room for companies that can differentiate products using better-supported active ingredients and controlled clinical evidence.

 

Why are microneedling, laser, and combination procedures gaining commercial importance?

The largest limitation of topical therapy is the transition from inflammatory striae rubrae to mature striae albae. As lesions become pale, atrophic, and structurally scar-like, simple surface moisturization produces limited improvement. NCBI notes that treatment objectives for mature striae increasingly center on stimulation of collagen and elastic fibers, while lasers, microneedling, radiofrequency, and other physical modalities are used to remodel deeper tissue.

Microneedling is gaining a strong position because it creates controlled micro-injuries that initiate repair and collagen remodeling without relying entirely on thermal energy. A systematic review and meta-analysis published in Aesthetic Plastic Surgery evaluated microneedling for striae distensae and supported its role as an effective treatment option. The procedure is also commercially attractive because patients commonly undergo a series of sessions rather than one treatment, creating recurring procedure revenue for dermatology clinics, plastic surgery practices, and medical spas.

FDA oversight is becoming more important as microneedling moves toward energy-assisted treatment. The FDA distinguishes medical microneedling devices from ordinary cosmetic tools and states that authorized microneedling devices are not automatically approved for delivery of topical drugs, cosmetics, vitamins, or platelet-rich plasma into the skin. In October 2025, the agency also warned about serious complications reported with some uses of radiofrequency microneedling, including burns, scarring, fat loss, disfigurement, and nerve damage. These developments increase the importance of physician training, device quality, indication-specific claims, and post-market safety, potentially favoring established manufacturers over low-cost unregulated systems.

Laser and light therapies form a premium procedure segment because different technologies can address different visual components of striae. Pulsed-dye lasers can target vascular redness in early striae rubrae, whereas fractional technologies stimulate collagen remodeling in mature lesions. NCBI notes that fractional lasers can stimulate fibroblast activity and collagen and elastin production, although pigmentation changes remain an important consideration, particularly for darker skin types.

The evidence increasingly favors individualized rather than one-device-fits-all treatment. A systematic review and meta-analysis comparing fractional microneedle radiofrequency with fractional CO2 laser found both approaches relevant for striae management, while another network meta-analysis of energy-based devices found no significant difference among several technologies in reduction of striae width. This supports a commercial shift toward multimodal platforms that allow providers to vary wavelength, energy delivery, depth, and treatment combinations according to striae stage and skin type.

Chemical peels and microdermabrasion remain lower-capital alternatives within clinics. Glycolic and trichloroacetic-acid peels are used for controlled resurfacing, while microdermabrasion mechanically exfoliates superficial skin. However, clinical evidence is less consistent than for some modern device-based approaches. These treatments therefore compete mainly through accessibility, lower procedure cost, minimal downtime, and their ability to be incorporated into combination aesthetic programs rather than through complete structural correction of mature striae.

 

How is broader aesthetic-procedure demand expanding the addressable market?

Stretch marks benefit commercially from growth in the wider aesthetic dermatology industry because clinics do not need to purchase equipment exclusively for striae. Devices used for skin resurfacing, scars, pigmentation, wrinkles, vascular lesions, and tightening can frequently be deployed across multiple aesthetic indications, improving equipment utilization and return on investment.

The International Society of Aesthetic Plastic Surgery reported nearly 38 million surgical and non-surgical aesthetic procedures worldwide in 2024, up more than 40% from 2020. Approximately 20.5 million were non-surgical procedures, and chemical peels and non-surgical skin tightening were among the most frequently performed non-surgical categories. The United States alone recorded more than 6.1 million aesthetic procedures, the highest country total in the ISAPS survey.

Consumer intent also remains high. The American Society for Dermatologic Surgery's 2025 survey of more than 3,500 U.S. consumers found that 70% were considering a cosmetic procedure, while 78% identified skin texture and/or discoloration as a concern. Cost was the leading hesitation for 24%, while 16% cited side effects or safety. These figures are not specific to stretch marks, but they show that the market is operating within a large consumer base already willing to consider professional improvement of visible skin texture.

The American Society of Plastic Surgeons also reported that skin resurfacing procedures increased 6% in 2024. Stretch-mark treatment can therefore be added to an existing resurfacing practice rather than requiring clinics to build a separate patient pathway, improving the economics of lasers and energy-based systems for providers.

 

How does limited reimbursement shape purchasing behavior?

Stretch marks are primarily treated as an aesthetic rather than medically necessary condition. Consequently, the market is driven largely by out-of-pocket consumer spending, unlike dermatology markets dependent on prescriptions, hospital reimbursement, or insurance coverage.

This structure favors lower-priced topical products for first-line self-treatment while creating a smaller but much higher-value procedural segment for consumers seeking stronger improvement. Patients commonly progress from creams and oils to microneedling, lasers, radiofrequency, or resurfacing when home treatment does not produce the desired cosmetic result.

The out-of-pocket model also changes competition among providers. Treatment price, number of required sessions, downtime, pigmentation risk, before-and-after evidence, physician reputation, and expected improvement become direct purchasing criteria. ASDS data showing cost, safety, pain, and uncertainty around results among the main reasons consumers delay cosmetic treatment illustrate why manufacturers increasingly compete through shorter downtime, treatment customization, safety features, and multi-indication platform economics.

 

Regional Analysis

North America

North America accounts for approximately 40% of preference for stretch-mark solutions, valued at approximately USD 1.18 billion in 2025 and projected to reach around USD 1.81 billion by 2032, growing at a CAGR of 6.3%, supported by high consumer spending on aesthetic skincare, large dermatology and med-spa networks, and strong penetration of laser and energy-based procedures. The United States is the region's key commercial market. ISAPS recorded more than 6.1 million aesthetic procedures in the U.S. during 2024, the highest national procedure volume globally, while the 2025 ASDS consumer survey found seven in ten respondents considering a cosmetic procedure.

Pregnancy provides a continuously renewed demand pool. CDC recorded 3.61 million U.S. births in 2025, and published pregnancy-related striae prevalence ranges from 43% to 88%. North America also has strong adoption of microneedling, fractional lasers, IPL, radiofrequency, chemical peels, and premium cosmeceuticals, creating demand across both home-use and clinic-based treatment tiers. FDA scrutiny of RF microneedling is likely to raise the importance of trained providers and compliant devices rather than materially reducing interest in professional skin remodeling.

Europe

Europe has a mature dermatology and aesthetic-medicine infrastructure, but reimbursement remains limited because stretch marks are usually treated as cosmetic, accounting for approximately 25% share of the global market, valued at around USD 0.74 billion in 2025, and growing at a CAGR of 6.3%. The UK NHS states that stretch marks are harmless and that treatment intended to make them less noticeable is generally not available through the NHS, reinforcing dependence on private spending for lasers, microneedling, and aesthetic skincare.

Pregnancy nevertheless continues to create a substantial recurring population. England and Wales recorded 585,396 live births in 2025. European demand increasingly favors treatments that can address both scarring and broader skin-resurfacing needs, improving the economics of multi-purpose fractional laser and energy platforms.

Asia-Pacific

Asia-Pacific offers one of the largest underlying populations for pregnancy-, puberty-, and weight-change-associated striae. China recorded 7.92 million births in 2025, providing a large annual pregnancy-related skincare and post-pregnancy aesthetic pool. More importantly, recent regional clinical evidence confirms high prevalence: a 2025 multicenter prospective study involving 1,017 Han Chinese pregnant women reported striae gravidarum in approximately 59% of participants. Asia-Pacific accounted for ~30% share of the global market, representing ~USD 0.89 billion in 2025, and is projected to grow at a CAGR of 6.3% during 2026–2032.

Skin-tone diversity also affects technology purchasing in Asia-Pacific. Because some energy-based approaches have higher risks of post-inflammatory hyperpigmentation in darker skin, adjustable fractional technologies, non-ablative devices, and microneedling can have a favorable positioning where providers prioritize pigmentation safety. Expanding medical-aesthetic clinics in China, Japan, South Korea, India, Australia, and Southeast Asia provide additional channels for both multinational equipment suppliers and premium topical brands.

Latin America

Latin America combines a significant pregnancy-related consumer population with exceptionally strong cultural adoption of cosmetic procedures. Brazil alone recorded 2.38 million births in 2024 and remains one of the world's largest aesthetic-procedure markets. ISAPS reported approximately 3.1 million cosmetic procedures in Brazil in 2024, second only to the United States in total procedure volume and first in surgical procedure volume. The Latin America region accounts for an estimated ~12% share of the global Stretch Marks Treatment Market, representing a market size of approximately USD 0.36 billion in 2025, and is projected to grow at a CAGR of 6.3% in line with the global market trajectory.

This established aesthetic infrastructure gives stretch-mark treatment a ready provider base. Fractional resurfacing, microneedling, scar revision, body contouring, and postpartum cosmetic services can be cross-sold to the same consumer population, particularly in Brazil, Mexico, Colombia, and other markets with established cosmetic medicine industries.

Middle East & Africa

The Middle East and Africa market is smaller, accounting for an estimated ~10% share of the global stretch marks treatment market, translating to a 2025 market size of approximately USD 296 million based on the global valuation of USD 2.96 billion, and is projected to grow at a CAGR of 6.3% (2026–2032), but benefits from private aesthetic clinics, medical tourism, premium beauty spending in Gulf countries, and large young populations in many African and Middle Eastern markets. ISAPS identified the UAE and Tunisia among the countries with the highest proportions of foreign aesthetic patients in 2024, indicating the importance of cross-border cosmetic treatment demand.

For stretch-mark treatment specifically, skin-tone safety is especially important. Pigmentary complications can be more visible after aggressive thermal treatment in darker Fitzpatrick skin types, increasing provider interest in carefully selected non-ablative fractional technologies, microneedling, and adjustable energy platforms. Manufacturers able to combine scar remodeling with broad skin-type compatibility therefore have a stronger positioning in this region.

 

Inside the Competitive Arena: Key Players Shaping Stretch Mark Treatments

Candela

Candela competes in stretch-mark treatment primarily through its Nordlys platform and Frax fractional technologies, alongside a wider portfolio that includes Vbeam, Gentle, PicoWay, Matrix, and other aesthetic and dermatologic systems. Candela has specifically published clinical material on treatment of striae with Frax 1550 on the Nordlys system, positioning fractional non-ablative resurfacing as part of a multi-indication platform rather than a standalone stretch-mark device. Nordlys combines fractional resurfacing with IPL and Nd technologies, allowing clinics to use one platform across pigmentation, vascular concerns, skin rejuvenation, scars, and striae. This portfolio breadth improves equipment utilization and enables providers to tailor treatment according to whether redness, pigmentation, or mature dermal texture is the principal concern.

Cynosure Lutronic

Cynosure Lutronic addresses stretch marks through a broad energy-based aesthetic portfolio led by Icon, together with platforms such as Elite iQ, Potenza, PicoSure, and other laser and radiofrequency systems. Icon specifically lists stretch-mark treatment alongside scars, pigmentation, vascular lesions, wrinkles, hair removal, and fractional resurfacing. Elite iQ similarly includes scars and stretch marks within its broad treatment portfolio. This multi-application strategy is commercially important because clinics can generate revenue from several high-volume indications while using the same capital equipment for striae patients. Cynosure's educational programs also include dedicated content on scars and striae management with Icon, reinforcing provider-driven adoption rather than positioning stretch marks as a purely consumer skincare problem.

Alma Lasers

Alma has one of the most explicitly diversified stretch-mark portfolios, including Alma Hybrid, Harmony XL PRO, Opus, and Alma PrimeX. Alma Hybrid combines an ablative 10,600-nm CO2 laser with a non-ablative 1570-nm laser, enabling physicians to adjust resurfacing depth and intensity. The company positions Harmony XL PRO for red stretch marks and Alma Hybrid for mature white striae, while its broader portfolio gives providers alternatives across different skin types and stages of striae. Alma also states that its stretch-mark solutions include options across Fitzpatrick skin types I–VI, which strengthens its positioning in increasingly important Asian, Middle Eastern, Latin American, and ethnically diverse North American patient populations.

Lumenis

Lumenis competes through the Stellar M22 multi-application platform and its ResurFX fractional non-ablative resurfacing technology. Stellar M22 is designed to address a wide range of aesthetic indications, including stretch marks, pigmentation, vascular concerns, scars, and skin rejuvenation. ResurFX provides fractional non-ablative resurfacing that can be used for scar and stretch-mark reduction while avoiding the tissue ablation associated with more aggressive CO2 procedures. This makes the platform relevant to practices seeking a balance between dermal remodeling and manageable recovery periods. The ability to use Stellar M22 across multiple aesthetic conditions also reduces dependence on stretch-mark procedure volume alone and strengthens the business case for platform investment.

 

What will define the next stage of the Stretch Marks Treatment Market from an analyst perspective?

Future competition in the stretch marks treatment market is shifting away from claims of full removal toward more realistic goals of visible, consistent improvement across different skin types and stages. A 2024 systematic review highlights that no single treatment is universally effective, which keeps demand open for fractional lasers, microneedling, radiofrequency, and combination therapies.

The market opportunity is split between low-cost topical products and higher-value clinical procedures. Early-stage users typically rely on creams and serums, while more established stretch marks drive demand for in-clinic treatments. This also supports growth in multi-use aesthetic platforms, such as laser and energy devices that treat stretch marks alongside scars, pigmentation, and skin rejuvenation.

Regulation and safety are becoming more important. The FDA has issued warnings and guidance around microneedling and radiofrequency microneedling safety, pushing providers toward devices with stronger clinical evidence, proper training, and regulatory clearance.

 

Stretch Marks Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.96 Billion
Revenue Forecast in 2032	USD 4.54 Billion
Overall Growth Rate	CAGR of 6.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Stretch Mark Type, By End User, By Geography
By Treatment Type	Topical Products [Tretinoin, Hyaluronic Acid, Centella Asiatica, Glycolic Acid, Emollients & Oils], Procedural Treatments [Microneedling, Radiofrequency Microneedling, Laser & Light Therapy, Chemical Peels, Microdermabrasion, Other Combination Treatments]
By Stretch Mark Type	Striae Rubrae, Striae Albae, Striae Gravidarum, Other Striae
By End User	Dermatology Clinics, Aesthetic Clinics & Medical Spas, Hospitals & Plastic Surgery Centers, Home-Use Consumers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for aesthetic skin treatments, growing adoption of minimally invasive procedures, increasing consumer preference for advanced skin remodeling solutions, expanding dermatology and medical spa networks, rising demand for pregnancy and post-weight-change stretch mark management
Customization Option	Available upon request